Improving Efficiency in Discovery and Development of Bispecifics and ADCs with Genedata Biologics
Festival of Biologics, Basel, Switzerland
November 2, 2022
Research and development (R&D) workflows for large-molecule therapeutics require comprehensive documentation of protocols, process parameters, as well as experimental entities including vectors, cell lines, expression and purification batches, and samples. We present a new registration platform, developed together with major biopharmas, which enables registration and tracking of biologics and the workflows used in their discovery and development. The platform can handle complex pools and mixtures, as well as diverse modalities including therapeutic proteins, viruses, mRNAs, and vaccines.
Here, we present concrete registration applications for highly engineered molecules such as bispecific antibodies and antibody drug conjugates (ADCs). Designed to interface and integrate with existing IT infrastructures, the platform can be configured to support corporate-specific variants of registration business logic such as proprietary molecule formats, uniqueness checks, or tailor-made naming conventions. The platform allows sharing molecule and sample ID spaces across both large- and small-molecule applications, substantially increasing efficiency and quality along the full R&D process.